FIELD: pharmaceutics.
SUBSTANCE: the suggested composition includes platinum-based compound with spatially complicated coordination and not platinum-based anti-cancer agent, and pharmaceutically acceptable carrier or solvent; the innovation deals with their application for obtaining medicinal preparation for inhibiting the growth of tumor cells in such a patient; with the method to inhibit the growth of tumor cells due to introducing for a patient efficient quantity of the mentioned therapeutic combined product or pharmaceutical composition that inhibits the growth of tumor cells according to the present innovation; in particular, when platinum-based compound with spatially complicated coordination is being (SP-4-3)-(cis-amine dichlorine-[2-methylpyridine]platinum (II) or its promedicine one should choose not platinum-based anti-cancer agent out of taxol, haemcytabin, navelbin, doxyl, 5-FU and taxoter. The present innovation enables to overcome resistance to cisplatin and prevent platinum-associated toxicity.
EFFECT: higher efficiency.
18 cl
Title | Year | Author | Number |
---|---|---|---|
COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
ANTITUMOR COMPOSITION CONTAINING TAXANE DERIVATIVES | 1993 |
|
RU2131250C1 |
METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
Authors
Dates
2006-10-10—Published
2001-05-10—Filed